sulfonylureas

(redirected from sulphonylureas)
Also found in: Medical.

sulfonylureas

These reduce the levels of glucose in the blood and are used to treat diabetes mellitus.
References in periodicals archive ?
Moreover, weight gain is usually more pronounced with pioglitazone use in combination with sulphonylureas and insulin in diabetic patients.
After Metformin in Pakistan the next two medications which can be added are from sulphonylureas or DPP-IV inhibitor groups.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33).
Speak to your doctor before significantly lowering your carbohydrate intake, especially if you are on medication that can cause low blood sugar, such as insulin, sulphonylureas or glinides.
Patients taking metformin, short-acting insulin secretagogues, sulphonylureas drugs or insulin will need to make adjustments to dose and or timings to reduce the risk of hypoglycemia while maintaining good glycemic control," the endocrinologist said.
Insulin and sulphonylureas like gliclazide have been shown to prevent kidney disease, blindness, amputations.
Of these 70% had hypoglycaemia with sulphonylureas.
The global diabetes drugs and devices market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug type (insulin derivatives - short-acting, intermediate-acting, long-acting, premixed, and rapid-acting insulin; oral anti-diabetes drugs - alpha-glucosidase inhibitors, biguanides, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylureas, thiazolidinediones; and non-insulin injectable anti-diabetes drugs - GLP-1 analogs), device type (diabetes monitoring and diagnostic devices - analog glucose meter, continuous glucose monitoring devices, glucose test strips, lancets and lancing devices; insulin delivery devices - insulin injectors, pens, pumps, syringes, etc.
The most severe mutations also cause neurological symptoms that, for unknown reasons, are less well treated by sulphonylureas.
New incretin-based therapies, such as the glucagon-like peptide 1 analogues and the di-peptidyl peptidose-4 inhibitors, carry an overall lower risk of hypoglycaemia than the sulphonylureas and insulin and are favoured agents to minimise the extent of hypoglycaemia while still ensuring that patients reach appropriate glucose control targets.
Certain medications may cause weight gain such as insulin, sulphonylureas, thiazolidinediones, atypical antipsychotics, steroids, anticonvulsants (phenytoin valproate), pizotifen, and hormonal contraceptives.
Sulphonylureas are the insulin secretagogues drugs acts via K+-ATP channel dependent way, where glucose metabolism in pancreatic A3/4 cells increases intracellular ATP/ADP ratio and leads to closure of K+-ATP channels.